Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2022 09:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board

SEATTLE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
July 28, 2022 16:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation, a Novel Approach for the Differentiation and Expansion of Induced Pluripotent Stem Cells to Generate Cytotoxic Innate Lymphocytes

New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™) as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACRTM...
June 30, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces Participation in Upcoming Scientific Summits

SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
June 16, 2022 08:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting

SEATTLE, June 16, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
June 10, 2022 10:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology

SEATTLE and PESSAC, France, June 10, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat...
May 23, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer

SEATTLE and DALLAS, May 23, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for...
May 19, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate, VivoVec Engineering for Improved in vivo CAR T cell Generation and Development of a Scalable Manufacturing Platform

UB-VV100 preclinical safety data demonstrates overall low risk for off target transduction and has a favorable safety and biodistribution profile Next generation VivoVec surface engineering promotes...
May 11, 2022 16:36 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall

Resignation effective immediatelyCEO Scharenberg assumes the role of interim Board Chair SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D....
May 04, 2022 10:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
May 03, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right